SynthesisEndocrine2026
Risk of cerebrovascular and cardiovascular events in acromegaly: a systematic review and meta-analysis.
Synthesis in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcromegaly is a rare endocrine disorder marked by chronic excess of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), which is associated with significant cardiovascular and cerebrovascular remodeling. While cardiovascular disease has long been the main cause of mortality, contemporary vascular risk remains unclear. This systematic review and meta-analysis quantified cerebrovascular and cardiovascular event risk in acromegaly versus the general population or matched controls.
methodsWe searched Databases up to September 2025 for cohort, case–control, cross-sectional, randomized, and registry-based studies reporting vascular outcomes in adults with acromegaly. Outcomes included heart failure, myocardial infarction, stroke, arrhythmias, valvular disease, cerebral aneurysm, vascular mortality, and venous thromboembolism. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using random-effects meta-analysis.
resultsEight studies (n ≈ 5,800 patients) were included. Acromegaly was associated with a significantly increased risk of heart failure (generic ratio effect of 1.82, 95% CI 1.17–2.83) and atrial fibrillation (generic ratio effect of 1.59, 95% CI 1.09–2.31). Risks of myocardial infarction (generic ratio effect of 0.91, 95% CI 0.65–1.28) and stroke (generic ratio effect of 1.10, 95% CI 0.80–1.53) were not significantly elevated. Additional outcomes included increased prevalence of valvular disease, left ventricular hypertrophy, cerebral aneurysm (in men), and venous thromboembolism. Evidence on cardiovascular mortality was mixed.
conclusionAcromegaly is associated with a significantly increased risk of heart failure and atrial fibrillation. Additionally, individual studies suggest a higher prevalence of valvular disease, thromboembolic events, and cerebral aneurysms, though these findings require confirmation in larger cohorts. These findings highlight the need for tailored cardiovascular surveillance strategies in acromegaly.
Indexed as
Identifiers
41801505What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.